Apremilast in psoriasis and beyond: Big hopes on a small molecule

Apremilast in psoriasis and beyond: Big hopes on a small molecule

Apremilast, an orally administered small molecule inhibitor of phosphodiesterase 4 (PDE4), has been licensed by the US Food and Drug Administration for the management of active psoriatic arthritis (March 21, 2014) and moderate to severe plaque psoriasis (September 23, 2014). It has got approval from...

Full description

Bibliographic Details
Main Authors: T P Afra, T Muhammed Razmi, Sunil Dogra
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Indian Dermatology Online Journal
Subjects:
Apremilast
efficacy
psoriasis
psoriatic arthritis
safety
small molecules
Online Access:http://www.idoj.in/article.asp?issn=2229-5178;year=2019;volume=10;issue=1;spage=1;epage=12;aulast=Afra

Internet

http://www.idoj.in/article.asp?issn=2229-5178;year=2019;volume=10;issue=1;spage=1;epage=12;aulast=Afra

Similar Items